This randomized clinical trial compares the effectiveness of platelets in additive solution treated with amotosalen–UV-A vs untreated platelets in plasma or in additive solution in patients with thrombocytopenia and malignant hematologic diseases
This study of a subcohort of women in the PROCAS study evaluates a panel of 18 single-nucleotide polymorphisms in combination with mammographic density for ability to improve classic breast cancer risk prediction.
This randomized clinical trial examines whether the previously reported improvement in local progression-free survival by adding regional hyperthermia to neoadjuvant chemotherapy vs chemotherapy alone translates into improved survival in patients with soft tissue sarcoma.
This secondary analysis of a randomized clinical trial examines the association between therapy with tumor-treating fields plus temozolomide and survival and health-related quality of life in patients with glioblastoma after completion of chemoradiotherapy.
This randomized clinical trial investigates the benefit of concurrent chemoradiotherapy vs radiotherapy alone in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIB squamous cell carcinoma of the uterine cervix.
This cohort study uses data from the prospective NIH-AARP Diet and Health Study to examine whether associations between duration of contraceptive use and ovarian, endometrial, breast, and colorectal cancer risk are altered by modifiable lifestyle characteristics.
This systematic review and meta-analysis evaluates the types of primary end points used in phase 2 checkpoint-inhibitor trials and assesses the strength of associations for objective response rate with progression-free and overall survival.
This phase 2 randomized clinical trial examines the treatment regimen of mFOLFOXIRI plus cetuximab followed by either cetuximab or bevacizumab for patients with RAS and BRAF wild-type metastatic colorectal cancer.
This cohort study of an ongoing phase 1 trial reports long-term clinical outcomes with atezolizumab therapy for patients with metastatic urothelial carcinoma.
This secondary analysis of a randomized clinical trial evaluates the prognostic value of 6 multigene signatures in women with early estrogen receptor–positive breast cancer who have received 5 years of endocrine therapy.
This modeling study calculates individualized residual risk estimates for patients with early-stage breast cancer and assesses whether defining eligibility based on a minimum residual risk threshold could increase the reliability of clinical trial power calculations.
This phase 2 randomized clinical trial evaluates the efficacy and safety of Sym004 (a mixture of futuximab and modotuximab) for the treatment of refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy.
This study compared response to ketoconazole treatment among patients with castration-resistant prostate cancer who had 0, 1, or 2 HSD3B1 variant alleles.
This cohort study evaluates whether the HSD3B1 (1245C) allele is associated with worse clinical outcomes from androgen-deprivation therapy for biochemical recurrence after radiotherapy.
This biomarker study examines the efficacy of irinotecan plus panitumumab in patients with advanced colorectal cancer whose tumors had high HER3 messenger RNA expression.
This database study analyzes trends in infused chemotherapy services performed in the physician office or hospital outpatient setting for commercially insured patients with cancer.
This study reports proof-of-principle early detection of chemotherapeutic-associated skin adverse drug reactions from social health networks using a deep learning–based signal generation pipeline to capture how patients describe cutaneous eruptions.
This cohort study examines recurrence outcomes in patients with fully resected gastroenteropancreatic neuroendocrine tumors.
This Insights characterizes recent advances and describes a framework for the treatment of advanced non–small cell lung cancer.
This Clinical Evidence Synopsis summarizes 12 randomized clinical trials to compare whether pathogen-reduced platelets are as effective as standard platelets for the prevention of bleeding in platelet transfusions.
A woman in her 20s taking valproic acid and phenytoin for epilepsy presented to the clinic with a 2-month history of gradually worsening pruritic plaques that initially involved the scalp, face, and neck, and later affected the anterior and posterior chest wall, abdomen, upper arms and thighs. What is your diagnosis?
This Viewpoint discusses the feasibility of shared decision making among primary care physicians and patients with respect to prostate cancer screening.
This Patient Page provides information on hormone therapy–related hot flashes and their management.
Create a personal account or sign in to: